Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of HIV-1 vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod in early treated HIV-1 infection
2018-002125-30Phase 2Recruiting
- Sponsor
- Aelix Therapeutics
- Start
- Nov 2018
- Modality
- Small Molecules, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MVA.HTI, ChAdOx1.HTI and vesatolimod in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Aelix Therapeutics. Primary endpoint: Solicited Grade 3 or 4 local reactions. Started Nov 2018; status: recruiting.
02
Drugs
MVA.HTIChAdOx1.HTIvesatolimod
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-002125-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002125-30.